Management and clinical outcomes after lung transplantation in patients with pre‐transplant <i>Mycobacterium abscessus</i> infection: A single center experience
A. Perez, Jonathan P. Singer, Brian S. Schwartz, Peter Chin‐Hong, Rupal Shah, Mary Ellen Kleinhenz, Ying Gao, Aida Venado, et al. (13 authors)
Transplant Infectious Disease · 2019-03
Abstract
BACKGROUND: Preoperative Mycobacterium abscessus infection is often considered a contraindication to lung transplantation because of its association with poor outcomes after transplant. Detailed strategies for bridging to transplant, post-operative management, and data regarding outcomes are lacking. METHODS: , BMI, LAS, antibiotic regimens, and other management decisions. Time to chronic lung allograft dysfunction (CLAD) and survival were also assessed. RESULTS: Of 387 lung transplant recipients, seven were infected with M abscessus at the time of listing. All received multiple antibiotics before transplant. While all subjects converted to smear negative for acid-fast bacilli before listing, five of the seven remained culture-positive at the time of transplant. After transplant, subjects received a median of 6 months of a multi-antibiotic regimen. One subject developed a post-operative M abscessus soft tissue infection that was treated medically. Six of the seven subjects survived the observation period; one died unrelated to M abscessus. Time to CLAD and survival were similar to a contemporary comparator group of CF transplant recipients. CONCLUSION: Lung transplant recipients with M abscessus infection have a low incidence of recurrent infection, excellent survival, and freedom from CLAD when an aggressive management and surveillance strategy is utilized. Given these findings, M abscessus infection may not be considered a contraindication to lung transplantation.
MeSH terms
- Medicine
- Mycobacterium abscessus
- Contraindication
- Transplantation
- Lung transplantation
- Surgery
- Internal medicine
- Incidence (geometry)
- Lung